Vera Therapeutics (VERA) Payables (2020 - 2026)

Vera Therapeutics has reported Payables for 7 years, with the latest figure at $88.9 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 50.03% year-over-year to $88.9 million; the trailing twelve-month figure through Mar 2026 stood at $88.9 million (up 50.03% YoY), and the FY2025 full-year result was $96.9 million, up 68.04% from the prior year.
• Payables for Q1 2026 stood at $88.9 million, down from $96.9 million in the prior quarter.
• The five-year high for Payables was $96.9 million in Q4 2025, with the low at $7.0 million in Q3 2022.
• Historically, Payables has averaged $51.4 million across 5 years, with a median of $54.7 million in 2024.
• Annual changes were most pronounced in 2022 — Payables jumped 627.39% — and 2024, when it dropped 5.65%.
• Vera Therapeutics' Payables stood at $37.0 million in 2022, then jumped by 65.22% to $61.1 million in 2023, then slipped by 5.65% to $57.7 million in 2024, then soared by 68.04% to $96.9 million in 2025, then slipped by 8.24% to $88.9 million in 2026.
• The last three Payables figures came in at $88.9 million (Q1 2026), $96.9 million (Q4 2025), and $93.0 million (Q3 2025), per Business Quant data.